Full-Time

Scientist 2 / Senior Scientist Nonclinical Development

Epicrispr Biotechnologies

Epicrispr Biotechnologies

11-50 employees

Epigenetic gene-expression therapy platform

Compensation Overview

$130k - $160k/yr

San Bruno, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Medicinal Chemistry
Pharmacology
Requirements
  • Ph.D. or equivalent in medicinal chemistry, pharmacology, or related discipline, with a minimum of 5 years of related experience in biotechnology or pharmaceutical industry
  • Demonstrated experience working with regulatory agencies, including leading interactions with FDA, EMA, and/or other relevant agencies
  • Strong preclinical experience in gene therapy
  • Demonstrated ability to work with CRO and to collaborate with cross-functional teams and external partners, including regulatory agencies, academic institutions, and biotech companies
  • Technical understanding of gene therapy and CRISPR based technologies
  • Strong communication skills
  • Strong analytical and problem-solving skills
  • Ability to work in a fast-paced environment, manage multiple projects, and meet deadlines
Responsibilities
  • Design, oversee, perform and interpret in vivo nonclinical studies (non-GLP and GLP), including proof-of-concepts, pharmacology, biodistribution, and toxicology studies within established timelines
  • Manage CROs and external partners
  • Write, review, and edit preclinical study reports and nonclinical sections of regulatory submissions
  • Partner with platform development scientists to inform candidate selection strategy
  • Develop pharmacodynamic biomarker strategy across programs and work closely with bioanalytical scientists to ensure efficient hands-off
  • Maintain up-to-date knowledge of regulatory guidance
  • Communicate effectively with Key Opinion Leaders (KOLs) to maintain up-to-date understanding of the literature
  • Develop strategies for preclinical development, including the identification and management of risks and opportunities
Desired Qualifications
  • Bioanalytical experience is preferred
Epicrispr Biotechnologies

Epicrispr Biotechnologies

View

Epicrispr Biotechnologies develops gene expression modulation therapies using epigenetics to treat complex diseases. Its Gene Expression Modulation System (GEMS) is a platform that lets researchers mix and match a toolbox of epigenomic modulators to tailor therapies by regulating gene expression in mammalian cells. Unlike competitors that rely on a single product, GEMS offers a flexible, customizable approach to create therapies for different diseases and patient needs. The company's goal is to expand genetic medicine by delivering targeted, epigenetically guided therapies through hospitals and clinics, while advancing scientific research.

Company Size

11-50

Company Stage

Series B

Total Funding

$123M

Headquarters

South San Francisco, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • $68M Series B in March 2025 funds EPI-321 Phase 1 trials.
  • Kite partnership expands GEMS into oncology CAR-T therapies.
  • First patient dosed in FSHD trial August 2025.

What critics are saying

  • EPI-321 Phase 1 fails on safety or efficacy by mid-2026.
  • Kite terminates CAR-T collaboration in 18 months due to reprioritization.
  • Broad Institute sues over CRISPR IP within 12 months.

What makes Epicrispr Biotechnologies unique

  • GEMS platform modulates gene expression epigenetically without cutting DNA.
  • EPI-321 silences DUX4 gene for FSHD using single AAV vector.
  • Mix-and-match toolbox creates customized therapies for multiple diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Epicrispr Biotechnologies who can refer or advise you

Benefits

Health Insurance

Paid Vacation

Flexible Work Hours

Remote Work Options

401(k) Retirement Plan

Gym Membership

Mental Health Support

Wellness Program

Conference Attendance Budget

Professional Development Budget

Training Programs

Employee Stock Purchase Plan

Stock Options

Company Equity

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
PharmiWeb.com
Mar 24th, 2026
Epicrispr Biotechnologies named to Fast Company's annual list of the World's Most Innovative Companies of 2026.

Epicrispr Biotechnologies named to Fast Company's annual list of the World's Most Innovative Companies of 2026. SAN FRANCISCO-(BUSINESS WIRE)-#FCMostInnovative-Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026, ranking among the top companies in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recognized by Fast Company as one of the world's most innovative companies," said Amber Salzman, Ph.D., Chief Executive Officer, Epicrispr Biotechnologies. "At Epicrispr, our focus is on unlocking the full potential of gene regulation to treat diseases that have long been considered untreatable. This recognition reflects the strength of our platform and the urgency of delivering transformative therapies to patients with neuromuscular diseases such as FSHD." FSHD, or facioscapulohumeral muscular dystrophy, is a progressive genetic muscle disorder that affects approximately 1 in 8,000 individuals worldwide, leading to skeletal muscle degeneration and severe loss of function. There are currently no approved disease-modifying therapies for FSHD. Epicrispr's lead candidate, EPI-321, is the first and only epigenetic editing therapy to receive IND authorization within the U.S. and is currently being evaluated in a first-in-human Phase 1/2 trial in the U.S., New Zealand, and Australia. EPI-321 has received FDA Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for FSHD. Designed to suppress pathogenic gene activity without cutting DNA, EPI-321 targets the root cause of FSHD and has the potential to be a one-time, disease-modifying, curative therapy for this progressive neuromuscular condition affecting more than one million people globally. To date, eight participants have been dosed, with early data showing favorable improvements across surrogate biomarkers and functional measures, with no serious adverse events reported. While clinical data is preliminary, there is compelling evidence of patients gaining muscle strength, increasing speed in various timed assessments, and gains in muscle mass. The World's Most Innovative Companies is Fast Company's trademark franchise and one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company's editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. "Our list of the Most Innovative Companies is about spotlighting organizations that don't just adapt to change - they drive it," said Brendan Vaughan, editor-in-chief of Fast Company. "The companies we honor this year are redefining what leadership looks like in 2026, pairing bold ideas with measurable impact and turning breakthrough innovation into real-world value. They are setting the pace for their industries and offering a blueprint for what sustained innovation can achieve." The full list of Fast Company's Most Innovative Companies honorees can now be found at fastcompany.com. It will also be available on newsstands beginning March 31, 2026. About Epicrispr Biotechnologies Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company's proprietary Gene Expression Modulation System (GEMS) enables precise and durable control of gene expression, unlocking first-in-class treatments for previously untreatable conditions. Epicrispr's lead program, EPI-321 is in clinical trials for FSHD, and the company is advancing additional gene-modulating therapies. Learn more at www.epicrispr.com or follow us on LinkedIn. Editor details. * Company: * Businesswire Last Updated: 24-Mar-2026

Business Wire
Dec 8th, 2025
Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference

Epicrispr Biotechnologies to present at 44th Annual J.P. Morgan Healthcare Conference. SAN FRANCISCO-(BUSINESS WIRE)-Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that Amber Salzman, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:00 a.m. PT. "Our first year as a clinical-stage company has reinforced the promise of epigenetic editing to precisely and durably control gene expression without cutting DNA," said Amber Salzman, Ph.D., CEO, Epicrispr. "We look forward to sharing our progress at the J.P. Morgan Healthcare Conference as we begin generating meaningful patient data and advance a pipeline of one-time, gene-modulating therapies for difficult-to-treat diseases, beginning with neuromuscular disease." A live webcast of the presentation will be available on the Epicrispr website under the News section at: https://epicrispr.com/news. An archived replay of the webcast will remain available for approximately 30 days following the event. About Epicrispr Biotechnologies Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company's proprietary Gene Expression Modulation System (GEMS) enables precise, durable control of gene expression, unlocking first-in-class treatments for previously untreatable conditions. Epicrispr's lead program, EPI-321 is in clinical trials for FSHD, and the company is advancing additional gene-modulating therapies. Learn more at www.epicrispr.com or follow us on LinkedIn.

DealForma
Aug 25th, 2025
Gene Therapy & Vectors R&D Partnerships, M&A and Venture Funding - H1 2025 Review

RhyGaze raised $86 million (series A, Jan) for its cone optogenetics vision-restoration platform, while Epicrispr secured $68 million (series B, Mar) to advance EPI-321, the first epigenetic therapy in trials for FSHD.

Business Wire
Apr 23rd, 2025
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study

Epicrispr is advancing EPI-321 with support from a $68 million Series B financing led by Ally Bridge Group and SOLVE FSHD.

The Business Journals
Mar 26th, 2025
Next-generation CRISPR company raises $68 million, zeroes in on first clinical trial

Why Lululemon's founder is outfitting this Bay Area biotech startup